nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—Paclitaxel—lung cancer	0.362	0.556	CbGbCtD
Rasagiline—BCL2—Docetaxel—lung cancer	0.262	0.402	CbGbCtD
Rasagiline—CYP1A2—Erlotinib—lung cancer	0.0155	0.0238	CbGbCtD
Rasagiline—CYP1A2—Etoposide—lung cancer	0.0112	0.0172	CbGbCtD
Rasagiline—BCL2—Irinotecan—Topotecan—lung cancer	0.00411	1	CbGdCrCtD
Rasagiline—BCL2—respiratory system—lung cancer	0.00175	0.193	CbGeAlD
Rasagiline—BCL2—epithelium—lung cancer	0.00146	0.161	CbGeAlD
Rasagiline—BCL2—bone marrow—lung cancer	0.00103	0.113	CbGeAlD
Rasagiline—BCL2—lung—lung cancer	0.000931	0.102	CbGeAlD
Rasagiline—MAOB—respiratory system—lung cancer	0.00073	0.0802	CbGeAlD
Rasagiline—BCL2—lymph node—lung cancer	0.000637	0.07	CbGeAlD
Rasagiline—MAOB—bronchus—lung cancer	0.000601	0.066	CbGeAlD
Rasagiline—CYP1A2—respiratory system—lung cancer	0.00052	0.0571	CbGeAlD
Rasagiline—MAOB—cardiac atrium—lung cancer	0.000507	0.0557	CbGeAlD
Rasagiline—MAOB—lung—lung cancer	0.000388	0.0426	CbGeAlD
Rasagiline—CYP1A2—lung—lung cancer	0.000276	0.0303	CbGeAlD
Rasagiline—MAOB—lymph node—lung cancer	0.000265	0.0291	CbGeAlD
Rasagiline—Loss of consciousness—Docetaxel—lung cancer	6.37e-05	0.000315	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Paclitaxel—lung cancer	6.36e-05	0.000315	CcSEcCtD
Rasagiline—Dyspnoea—Etoposide—lung cancer	6.35e-05	0.000314	CcSEcCtD
Rasagiline—Somnolence—Etoposide—lung cancer	6.33e-05	0.000313	CcSEcCtD
Rasagiline—Cough—Docetaxel—lung cancer	6.33e-05	0.000313	CcSEcCtD
Rasagiline—Angina pectoris—Doxorubicin—lung cancer	6.33e-05	0.000313	CcSEcCtD
Rasagiline—Insomnia—Paclitaxel—lung cancer	6.31e-05	0.000313	CcSEcCtD
Rasagiline—Epistaxis—Methotrexate—lung cancer	6.31e-05	0.000312	CcSEcCtD
Rasagiline—Hypersensitivity—Irinotecan—lung cancer	6.31e-05	0.000312	CcSEcCtD
Rasagiline—Convulsion—Docetaxel—lung cancer	6.28e-05	0.000311	CcSEcCtD
Rasagiline—Paraesthesia—Paclitaxel—lung cancer	6.27e-05	0.00031	CcSEcCtD
Rasagiline—Hypertension—Docetaxel—lung cancer	6.26e-05	0.00031	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—UGT1A1—lung cancer	6.25e-05	0.000465	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	6.23e-05	0.000464	CbGpPWpGaD
Rasagiline—Dyspnoea—Paclitaxel—lung cancer	6.22e-05	0.000308	CcSEcCtD
Rasagiline—Somnolence—Paclitaxel—lung cancer	6.21e-05	0.000307	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—lung cancer	6.2e-05	0.000461	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTP1—lung cancer	6.19e-05	0.000461	CbGpPWpGaD
Rasagiline—Decreased appetite—Etoposide—lung cancer	6.19e-05	0.000306	CcSEcCtD
Rasagiline—Arthralgia—Docetaxel—lung cancer	6.17e-05	0.000306	CcSEcCtD
Rasagiline—Chest pain—Docetaxel—lung cancer	6.17e-05	0.000306	CcSEcCtD
Rasagiline—Nausea—Vinorelbine—lung cancer	6.16e-05	0.000305	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Etoposide—lung cancer	6.15e-05	0.000304	CcSEcCtD
Rasagiline—Dyspepsia—Paclitaxel—lung cancer	6.14e-05	0.000304	CcSEcCtD
Rasagiline—Body temperature increased—Cisplatin—lung cancer	6.14e-05	0.000304	CcSEcCtD
Rasagiline—Asthenia—Irinotecan—lung cancer	6.14e-05	0.000304	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	6.13e-05	0.000303	CcSEcCtD
Rasagiline—Constipation—Etoposide—lung cancer	6.09e-05	0.000301	CcSEcCtD
Rasagiline—Dysuria—Doxorubicin—lung cancer	6.07e-05	0.000301	CcSEcCtD
Rasagiline—Decreased appetite—Paclitaxel—lung cancer	6.07e-05	0.0003	CcSEcCtD
Rasagiline—Dry mouth—Docetaxel—lung cancer	6.04e-05	0.000299	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Doxorubicin—lung cancer	6.04e-05	0.000299	CcSEcCtD
Rasagiline—Haemoglobin—Methotrexate—lung cancer	6.03e-05	0.000299	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	6.03e-05	0.000448	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Paclitaxel—lung cancer	6.03e-05	0.000298	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—FOXO3—lung cancer	6.02e-05	0.000448	CbGpPWpGaD
Rasagiline—Haemorrhage—Methotrexate—lung cancer	6e-05	0.000297	CcSEcCtD
Rasagiline—BCL2—Immune System—FGR—lung cancer	6e-05	0.000446	CbGpPWpGaD
Rasagiline—Pollakiuria—Doxorubicin—lung cancer	6e-05	0.000297	CcSEcCtD
Rasagiline—Asthenia—Gemcitabine—lung cancer	5.98e-05	0.000296	CcSEcCtD
Rasagiline—Constipation—Paclitaxel—lung cancer	5.97e-05	0.000296	CcSEcCtD
Rasagiline—Confusional state—Docetaxel—lung cancer	5.97e-05	0.000295	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	5.94e-05	0.000442	CbGpPWpGaD
Rasagiline—Urinary tract disorder—Methotrexate—lung cancer	5.93e-05	0.000293	CcSEcCtD
Rasagiline—Photosensitivity reaction—Doxorubicin—lung cancer	5.93e-05	0.000293	CcSEcCtD
Rasagiline—Pruritus—Gemcitabine—lung cancer	5.9e-05	0.000292	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—SRC—lung cancer	5.89e-05	0.000438	CbGpPWpGaD
Rasagiline—Urethral disorder—Methotrexate—lung cancer	5.88e-05	0.000291	CcSEcCtD
Rasagiline—Infection—Docetaxel—lung cancer	5.88e-05	0.000291	CcSEcCtD
Rasagiline—Weight decreased—Doxorubicin—lung cancer	5.87e-05	0.000291	CcSEcCtD
Rasagiline—Feeling abnormal—Etoposide—lung cancer	5.87e-05	0.00029	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	5.86e-05	0.000436	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—RRM1—lung cancer	5.86e-05	0.000436	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTA3—lung cancer	5.86e-05	0.000436	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—lung cancer	5.86e-05	0.000436	CbGpPWpGaD
Rasagiline—Diarrhoea—Irinotecan—lung cancer	5.86e-05	0.00029	CcSEcCtD
Rasagiline—Gastrointestinal pain—Etoposide—lung cancer	5.82e-05	0.000288	CcSEcCtD
Rasagiline—Shock—Docetaxel—lung cancer	5.82e-05	0.000288	CcSEcCtD
Rasagiline—Nervous system disorder—Docetaxel—lung cancer	5.8e-05	0.000287	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—lung cancer	5.79e-05	0.000287	CcSEcCtD
Rasagiline—Infestation NOS—Doxorubicin—lung cancer	5.79e-05	0.000287	CcSEcCtD
Rasagiline—Feeling abnormal—Paclitaxel—lung cancer	5.75e-05	0.000285	CcSEcCtD
Rasagiline—Skin disorder—Docetaxel—lung cancer	5.75e-05	0.000285	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VEGFA—lung cancer	5.73e-05	0.000426	CbGpPWpGaD
Rasagiline—Hypersensitivity—Cisplatin—lung cancer	5.73e-05	0.000283	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	5.71e-05	0.000425	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Paclitaxel—lung cancer	5.71e-05	0.000283	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—lung cancer	5.7e-05	0.000424	CbGpPWpGaD
Rasagiline—Diarrhoea—Gemcitabine—lung cancer	5.7e-05	0.000282	CcSEcCtD
Rasagiline—CYP1A2—Phase II conjugation—GSTM1—lung cancer	5.69e-05	0.000423	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Doxorubicin—lung cancer	5.68e-05	0.000281	CcSEcCtD
Rasagiline—Dizziness—Irinotecan—lung cancer	5.66e-05	0.00028	CcSEcCtD
Rasagiline—Urticaria—Etoposide—lung cancer	5.66e-05	0.00028	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—lung cancer	5.64e-05	0.000279	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—lung cancer	5.64e-05	0.000279	CcSEcCtD
Rasagiline—Anorexia—Docetaxel—lung cancer	5.64e-05	0.000279	CcSEcCtD
Rasagiline—Abdominal pain—Etoposide—lung cancer	5.63e-05	0.000279	CcSEcCtD
Rasagiline—Body temperature increased—Etoposide—lung cancer	5.63e-05	0.000279	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—lung cancer	5.63e-05	0.000279	CcSEcCtD
Rasagiline—Eye disorder—Methotrexate—lung cancer	5.61e-05	0.000278	CcSEcCtD
Rasagiline—CYP1A2—Tryptophan metabolism—MDM2—lung cancer	5.59e-05	0.000416	CbGpPWpGaD
Rasagiline—Asthenia—Cisplatin—lung cancer	5.58e-05	0.000276	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—lung cancer	5.57e-05	0.000415	CbGpPWpGaD
Rasagiline—Cardiac disorder—Methotrexate—lung cancer	5.57e-05	0.000276	CcSEcCtD
Rasagiline—Sweating—Doxorubicin—lung cancer	5.55e-05	0.000275	CcSEcCtD
Rasagiline—Urticaria—Paclitaxel—lung cancer	5.55e-05	0.000275	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—lung cancer	5.53e-05	0.000411	CbGpPWpGaD
Rasagiline—Hypotension—Docetaxel—lung cancer	5.53e-05	0.000274	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—lung cancer	5.52e-05	0.000273	CcSEcCtD
Rasagiline—Abdominal pain—Paclitaxel—lung cancer	5.52e-05	0.000273	CcSEcCtD
Rasagiline—Body temperature increased—Paclitaxel—lung cancer	5.52e-05	0.000273	CcSEcCtD
Rasagiline—MAOB—Metabolism—B4GALT5—lung cancer	5.51e-05	0.00041	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	5.47e-05	0.000407	CbGpPWpGaD
Rasagiline—Epistaxis—Doxorubicin—lung cancer	5.46e-05	0.00027	CcSEcCtD
Rasagiline—Angiopathy—Methotrexate—lung cancer	5.45e-05	0.00027	CcSEcCtD
Rasagiline—Vomiting—Irinotecan—lung cancer	5.44e-05	0.000269	CcSEcCtD
Rasagiline—Immune system disorder—Methotrexate—lung cancer	5.42e-05	0.000268	CcSEcCtD
Rasagiline—Mediastinal disorder—Methotrexate—lung cancer	5.41e-05	0.000268	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	5.4e-05	0.000402	CbGpPWpGaD
Rasagiline—Rash—Irinotecan—lung cancer	5.4e-05	0.000267	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—lung cancer	5.39e-05	0.000401	CbGpPWpGaD
Rasagiline—Dermatitis—Irinotecan—lung cancer	5.39e-05	0.000267	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Docetaxel—lung cancer	5.39e-05	0.000267	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—HPGDS—lung cancer	5.39e-05	0.000401	CbGpPWpGaD
Rasagiline—Chills—Methotrexate—lung cancer	5.39e-05	0.000267	CcSEcCtD
Rasagiline—Headache—Irinotecan—lung cancer	5.36e-05	0.000265	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTA4—lung cancer	5.36e-05	0.000399	CbGpPWpGaD
Rasagiline—Insomnia—Docetaxel—lung cancer	5.35e-05	0.000265	CcSEcCtD
Rasagiline—Diarrhoea—Cisplatin—lung cancer	5.32e-05	0.000263	CcSEcCtD
Rasagiline—Paraesthesia—Docetaxel—lung cancer	5.31e-05	0.000263	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—lung cancer	5.3e-05	0.000263	CcSEcCtD
Rasagiline—Vomiting—Gemcitabine—lung cancer	5.3e-05	0.000262	CcSEcCtD
Rasagiline—Dyspnoea—Docetaxel—lung cancer	5.28e-05	0.000261	CcSEcCtD
Rasagiline—Somnolence—Docetaxel—lung cancer	5.26e-05	0.00026	CcSEcCtD
Rasagiline—Mental disorder—Methotrexate—lung cancer	5.26e-05	0.00026	CcSEcCtD
Rasagiline—Rash—Gemcitabine—lung cancer	5.26e-05	0.00026	CcSEcCtD
Rasagiline—Dermatitis—Gemcitabine—lung cancer	5.25e-05	0.00026	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	5.25e-05	0.000391	CbGpPWpGaD
Rasagiline—Hypersensitivity—Etoposide—lung cancer	5.25e-05	0.00026	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTT1—lung cancer	5.23e-05	0.000389	CbGpPWpGaD
Rasagiline—Malnutrition—Methotrexate—lung cancer	5.23e-05	0.000259	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—lung cancer	5.22e-05	0.000259	CcSEcCtD
Rasagiline—Headache—Gemcitabine—lung cancer	5.22e-05	0.000259	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTA2—lung cancer	5.22e-05	0.000388	CbGpPWpGaD
Rasagiline—Rhinitis—Doxorubicin—lung cancer	5.21e-05	0.000258	CcSEcCtD
Rasagiline—Dyspepsia—Docetaxel—lung cancer	5.21e-05	0.000258	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—lung cancer	5.21e-05	0.000387	CbGpPWpGaD
Rasagiline—Haemorrhage—Doxorubicin—lung cancer	5.2e-05	0.000257	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—lung cancer	5.17e-05	0.000256	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP2A6—lung cancer	5.17e-05	0.000384	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GCLC—lung cancer	5.17e-05	0.000384	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGFR—lung cancer	5.16e-05	0.000384	CbGpPWpGaD
Rasagiline—Decreased appetite—Docetaxel—lung cancer	5.14e-05	0.000255	CcSEcCtD
Rasagiline—Hypersensitivity—Paclitaxel—lung cancer	5.14e-05	0.000255	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	5.14e-05	0.000382	CbGpPWpGaD
Rasagiline—Urinary tract disorder—Doxorubicin—lung cancer	5.13e-05	0.000254	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—lung cancer	5.12e-05	0.000254	CcSEcCtD
Rasagiline—Dysgeusia—Methotrexate—lung cancer	5.12e-05	0.000253	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Docetaxel—lung cancer	5.11e-05	0.000253	CcSEcCtD
Rasagiline—Asthenia—Etoposide—lung cancer	5.11e-05	0.000253	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—lung cancer	5.11e-05	0.000253	CcSEcCtD
Rasagiline—BCL2—Immune System—ADCY1—lung cancer	5.1e-05	0.00038	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NCAM1—lung cancer	5.1e-05	0.00038	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—lung cancer	5.1e-05	0.000379	CbGpPWpGaD
Rasagiline—Urethral disorder—Doxorubicin—lung cancer	5.1e-05	0.000252	CcSEcCtD
Rasagiline—Nausea—Irinotecan—lung cancer	5.08e-05	0.000252	CcSEcCtD
Rasagiline—Constipation—Docetaxel—lung cancer	5.06e-05	0.000251	CcSEcCtD
Rasagiline—Back pain—Methotrexate—lung cancer	5.05e-05	0.00025	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—lung cancer	5.04e-05	0.000375	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTA1—lung cancer	5.04e-05	0.000375	CbGpPWpGaD
Rasagiline—Pruritus—Etoposide—lung cancer	5.04e-05	0.000249	CcSEcCtD
Rasagiline—Asthenia—Paclitaxel—lung cancer	5.01e-05	0.000248	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—lung cancer	5e-05	0.000372	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ABCC3—lung cancer	4.98e-05	0.000371	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PPP2R1B—lung cancer	4.97e-05	0.00037	CbGpPWpGaD
Rasagiline—Nausea—Gemcitabine—lung cancer	4.95e-05	0.000245	CcSEcCtD
Rasagiline—Vomiting—Cisplatin—lung cancer	4.94e-05	0.000245	CcSEcCtD
Rasagiline—Pruritus—Paclitaxel—lung cancer	4.94e-05	0.000245	CcSEcCtD
Rasagiline—Rash—Cisplatin—lung cancer	4.9e-05	0.000243	CcSEcCtD
Rasagiline—Dermatitis—Cisplatin—lung cancer	4.9e-05	0.000242	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ERBB3—lung cancer	4.88e-05	0.000363	CbGpPWpGaD
Rasagiline—Feeling abnormal—Docetaxel—lung cancer	4.88e-05	0.000241	CcSEcCtD
Rasagiline—Diarrhoea—Etoposide—lung cancer	4.87e-05	0.000241	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—lung cancer	4.86e-05	0.000362	CbGpPWpGaD
Rasagiline—Eye disorder—Doxorubicin—lung cancer	4.86e-05	0.00024	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	4.85e-05	0.000361	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Methotrexate—lung cancer	4.85e-05	0.00024	CcSEcCtD
Rasagiline—Gastrointestinal pain—Docetaxel—lung cancer	4.84e-05	0.00024	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—lung cancer	4.83e-05	0.000239	CcSEcCtD
Rasagiline—MAOB—Metabolism—AKR1C1—lung cancer	4.83e-05	0.000359	CbGpPWpGaD
Rasagiline—Cardiac disorder—Doxorubicin—lung cancer	4.82e-05	0.000239	CcSEcCtD
Rasagiline—Diarrhoea—Paclitaxel—lung cancer	4.78e-05	0.000236	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	4.73e-05	0.000351	CbGpPWpGaD
Rasagiline—Angiopathy—Doxorubicin—lung cancer	4.72e-05	0.000233	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—lung cancer	4.71e-05	0.000351	CbGpPWpGaD
Rasagiline—Malaise—Methotrexate—lung cancer	4.71e-05	0.000233	CcSEcCtD
Rasagiline—Dizziness—Etoposide—lung cancer	4.71e-05	0.000233	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—lung cancer	4.69e-05	0.000232	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—lung cancer	4.69e-05	0.000232	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—lung cancer	4.68e-05	0.000232	CcSEcCtD
Rasagiline—MAOB—Metabolism—UGT1A1—lung cancer	4.68e-05	0.000348	CbGpPWpGaD
Rasagiline—Abdominal pain—Docetaxel—lung cancer	4.68e-05	0.000232	CcSEcCtD
Rasagiline—Body temperature increased—Docetaxel—lung cancer	4.68e-05	0.000232	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—lung cancer	4.68e-05	0.000232	CcSEcCtD
Rasagiline—Chills—Doxorubicin—lung cancer	4.66e-05	0.000231	CcSEcCtD
Rasagiline—BCL2—Immune System—IRF1—lung cancer	4.64e-05	0.000345	CbGpPWpGaD
Rasagiline—Dizziness—Paclitaxel—lung cancer	4.62e-05	0.000229	CcSEcCtD
Rasagiline—Nausea—Cisplatin—lung cancer	4.62e-05	0.000229	CcSEcCtD
Rasagiline—Alopecia—Doxorubicin—lung cancer	4.59e-05	0.000227	CcSEcCtD
Rasagiline—Cough—Methotrexate—lung cancer	4.56e-05	0.000226	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—lung cancer	4.55e-05	0.000225	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—FGFR1—lung cancer	4.54e-05	0.000338	CbGpPWpGaD
Rasagiline—Convulsion—Methotrexate—lung cancer	4.53e-05	0.000224	CcSEcCtD
Rasagiline—Vomiting—Etoposide—lung cancer	4.53e-05	0.000224	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—lung cancer	4.52e-05	0.000224	CcSEcCtD
Rasagiline—MAOB—Metabolism—GNG11—lung cancer	4.52e-05	0.000336	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—BCL2L1—lung cancer	4.49e-05	0.000334	CbGpPWpGaD
Rasagiline—Rash—Etoposide—lung cancer	4.49e-05	0.000222	CcSEcCtD
Rasagiline—Dermatitis—Etoposide—lung cancer	4.48e-05	0.000222	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—lung cancer	4.48e-05	0.000334	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EP300—lung cancer	4.48e-05	0.000334	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—lung cancer	4.48e-05	0.000333	CbGpPWpGaD
Rasagiline—Headache—Etoposide—lung cancer	4.46e-05	0.000221	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—lung cancer	4.46e-05	0.000221	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	4.46e-05	0.000332	CbGpPWpGaD
Rasagiline—Chest pain—Methotrexate—lung cancer	4.45e-05	0.00022	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—lung cancer	4.45e-05	0.00022	CcSEcCtD
Rasagiline—Vomiting—Paclitaxel—lung cancer	4.44e-05	0.00022	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—lung cancer	4.43e-05	0.000219	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—POMC—lung cancer	4.43e-05	0.00033	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	4.42e-05	0.000219	CcSEcCtD
Rasagiline—Rash—Paclitaxel—lung cancer	4.4e-05	0.000218	CcSEcCtD
Rasagiline—Dermatitis—Paclitaxel—lung cancer	4.4e-05	0.000218	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—lung cancer	4.4e-05	0.000327	CbGpPWpGaD
Rasagiline—Discomfort—Methotrexate—lung cancer	4.4e-05	0.000218	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP2E1—lung cancer	4.39e-05	0.000327	CbGpPWpGaD
Rasagiline—Back pain—Doxorubicin—lung cancer	4.38e-05	0.000217	CcSEcCtD
Rasagiline—Headache—Paclitaxel—lung cancer	4.37e-05	0.000217	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—lung cancer	4.36e-05	0.000324	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—SRC—lung cancer	4.36e-05	0.000324	CbGpPWpGaD
Rasagiline—Hypersensitivity—Docetaxel—lung cancer	4.36e-05	0.000216	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—lung cancer	4.35e-05	0.000215	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP2E1—lung cancer	4.33e-05	0.000322	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	4.31e-05	0.000321	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—lung cancer	4.3e-05	0.00032	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALDOA—lung cancer	4.3e-05	0.00032	CbGpPWpGaD
Rasagiline—Confusional state—Methotrexate—lung cancer	4.3e-05	0.000213	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—lung cancer	4.25e-05	0.000316	CbGpPWpGaD
Rasagiline—Asthenia—Docetaxel—lung cancer	4.25e-05	0.00021	CcSEcCtD
Rasagiline—Infection—Methotrexate—lung cancer	4.24e-05	0.00021	CcSEcCtD
Rasagiline—Nausea—Etoposide—lung cancer	4.23e-05	0.000209	CcSEcCtD
Rasagiline—BCL2—Immune System—APP—lung cancer	4.23e-05	0.000315	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Doxorubicin—lung cancer	4.2e-05	0.000208	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—lung cancer	4.2e-05	0.000312	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGF9—lung cancer	4.19e-05	0.000312	CbGpPWpGaD
Rasagiline—Pruritus—Docetaxel—lung cancer	4.19e-05	0.000207	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—lung cancer	4.18e-05	0.000207	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—lung cancer	4.18e-05	0.000207	CcSEcCtD
Rasagiline—MAOB—Metabolism—NCOA3—lung cancer	4.18e-05	0.000311	CbGpPWpGaD
Rasagiline—Agitation—Doxorubicin—lung cancer	4.16e-05	0.000206	CcSEcCtD
Rasagiline—Nausea—Paclitaxel—lung cancer	4.15e-05	0.000205	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—lung cancer	4.14e-05	0.000205	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—HRAS—lung cancer	4.14e-05	0.000308	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Methotrexate—lung cancer	4.12e-05	0.000204	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—lung cancer	4.08e-05	0.000202	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—lung cancer	4.07e-05	0.000201	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—lung cancer	4.07e-05	0.000201	CcSEcCtD
Rasagiline—MAOB—Metabolism—ABCG2—lung cancer	4.06e-05	0.000302	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ADCY1—lung cancer	4.06e-05	0.000302	CbGpPWpGaD
Rasagiline—Syncope—Doxorubicin—lung cancer	4.06e-05	0.000201	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—lung cancer	4.05e-05	0.000201	CcSEcCtD
Rasagiline—Diarrhoea—Docetaxel—lung cancer	4.05e-05	0.0002	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—lung cancer	3.98e-05	0.000197	CcSEcCtD
Rasagiline—MAOB—Metabolism—ENO2—lung cancer	3.98e-05	0.000296	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—HPGDS—lung cancer	3.98e-05	0.000296	CbGpPWpGaD
Rasagiline—Loss of consciousness—Doxorubicin—lung cancer	3.98e-05	0.000197	CcSEcCtD
Rasagiline—MAOB—Metabolism—PPP2R1B—lung cancer	3.96e-05	0.000294	CbGpPWpGaD
Rasagiline—Cough—Doxorubicin—lung cancer	3.95e-05	0.000195	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—KIT—lung cancer	3.94e-05	0.000293	CbGpPWpGaD
Rasagiline—Convulsion—Doxorubicin—lung cancer	3.92e-05	0.000194	CcSEcCtD
Rasagiline—Dizziness—Docetaxel—lung cancer	3.91e-05	0.000194	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—lung cancer	3.91e-05	0.000291	CbGpPWpGaD
Rasagiline—Hypertension—Doxorubicin—lung cancer	3.91e-05	0.000193	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—EGF—lung cancer	3.9e-05	0.00029	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Methotrexate—lung cancer	3.89e-05	0.000192	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTT1—lung cancer	3.86e-05	0.000287	CbGpPWpGaD
Rasagiline—Insomnia—Methotrexate—lung cancer	3.86e-05	0.000191	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—lung cancer	3.85e-05	0.000191	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—lung cancer	3.85e-05	0.000191	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—lung cancer	3.84e-05	0.00019	CcSEcCtD
Rasagiline—Paraesthesia—Methotrexate—lung cancer	3.83e-05	0.00019	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.83e-05	0.000189	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—lung cancer	3.82e-05	0.000284	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—lung cancer	3.82e-05	0.000284	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2A6—lung cancer	3.82e-05	0.000284	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GCLC—lung cancer	3.82e-05	0.000284	CbGpPWpGaD
Rasagiline—Discomfort—Doxorubicin—lung cancer	3.81e-05	0.000188	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—lung cancer	3.8e-05	0.000188	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—lung cancer	3.79e-05	0.000188	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—lung cancer	3.77e-05	0.000187	CcSEcCtD
Rasagiline—Vomiting—Docetaxel—lung cancer	3.76e-05	0.000186	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—lung cancer	3.75e-05	0.000186	CcSEcCtD
Rasagiline—Rash—Docetaxel—lung cancer	3.73e-05	0.000185	CcSEcCtD
Rasagiline—Dermatitis—Docetaxel—lung cancer	3.73e-05	0.000185	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—lung cancer	3.72e-05	0.000184	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—lung cancer	3.71e-05	0.000184	CcSEcCtD
Rasagiline—Headache—Docetaxel—lung cancer	3.71e-05	0.000184	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—lung cancer	3.68e-05	0.000182	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	3.67e-05	0.000273	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CASP8—lung cancer	3.67e-05	0.000273	CbGpPWpGaD
Rasagiline—Infection—Doxorubicin—lung cancer	3.67e-05	0.000182	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—IL6R—lung cancer	3.66e-05	0.000272	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—AKT1—lung cancer	3.66e-05	0.000272	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CREBBP—lung cancer	3.65e-05	0.000272	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	3.64e-05	0.000271	CbGpPWpGaD
Rasagiline—Shock—Doxorubicin—lung cancer	3.63e-05	0.00018	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—lung cancer	3.62e-05	0.00027	CbGpPWpGaD
Rasagiline—Nervous system disorder—Doxorubicin—lung cancer	3.62e-05	0.000179	CcSEcCtD
Rasagiline—MAOB—Metabolism—ENO1—lung cancer	3.62e-05	0.000269	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—lung cancer	3.61e-05	0.000269	CbGpPWpGaD
Rasagiline—Skin disorder—Doxorubicin—lung cancer	3.59e-05	0.000178	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—lung cancer	3.57e-05	0.000266	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Doxorubicin—lung cancer	3.57e-05	0.000177	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—lung cancer	3.52e-05	0.000174	CcSEcCtD
Rasagiline—Nausea—Docetaxel—lung cancer	3.51e-05	0.000174	CcSEcCtD
Rasagiline—Feeling abnormal—Methotrexate—lung cancer	3.51e-05	0.000174	CcSEcCtD
Rasagiline—BCL2—Immune System—FOXO3—lung cancer	3.51e-05	0.000261	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAP2K1—lung cancer	3.49e-05	0.000259	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Methotrexate—lung cancer	3.49e-05	0.000173	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CD—lung cancer	3.46e-05	0.000258	CbGpPWpGaD
Rasagiline—Hypotension—Doxorubicin—lung cancer	3.45e-05	0.000171	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—lung cancer	3.39e-05	0.000168	CcSEcCtD
Rasagiline—BCL2—Immune System—ITGB1—lung cancer	3.38e-05	0.000251	CbGpPWpGaD
Rasagiline—Body temperature increased—Methotrexate—lung cancer	3.37e-05	0.000167	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—lung cancer	3.37e-05	0.000167	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.36e-05	0.000167	CcSEcCtD
Rasagiline—Insomnia—Doxorubicin—lung cancer	3.34e-05	0.000165	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTM1—lung cancer	3.33e-05	0.000248	CbGpPWpGaD
Rasagiline—Paraesthesia—Doxorubicin—lung cancer	3.32e-05	0.000164	CcSEcCtD
Rasagiline—Dyspnoea—Doxorubicin—lung cancer	3.29e-05	0.000163	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTM1—lung cancer	3.28e-05	0.000244	CbGpPWpGaD
Rasagiline—Somnolence—Doxorubicin—lung cancer	3.28e-05	0.000163	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—lung cancer	3.25e-05	0.000161	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP2E1—lung cancer	3.25e-05	0.000242	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NQO1—lung cancer	3.21e-05	0.000239	CbGpPWpGaD
Rasagiline—Decreased appetite—Doxorubicin—lung cancer	3.21e-05	0.000159	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—lung cancer	3.19e-05	0.000158	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—lung cancer	3.16e-05	0.000156	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP1A1—lung cancer	3.16e-05	0.000235	CbGpPWpGaD
Rasagiline—Hypersensitivity—Methotrexate—lung cancer	3.14e-05	0.000156	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP1A1—lung cancer	3.11e-05	0.000232	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MDM2—lung cancer	3.1e-05	0.000231	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RAF1—lung cancer	3.09e-05	0.00023	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—lung cancer	3.07e-05	0.000228	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ERBB2—lung cancer	3.06e-05	0.000228	CbGpPWpGaD
Rasagiline—Asthenia—Methotrexate—lung cancer	3.06e-05	0.000151	CcSEcCtD
Rasagiline—BCL2—Immune System—CD8A—lung cancer	3.06e-05	0.000227	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—lung cancer	3.04e-05	0.000151	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MTOR—lung cancer	3.02e-05	0.000225	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CB—lung cancer	3.02e-05	0.000225	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Doxorubicin—lung cancer	3.02e-05	0.000149	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—lung cancer	3.02e-05	0.000149	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CD4—lung cancer	3.01e-05	0.000224	CbGpPWpGaD
Rasagiline—Urticaria—Doxorubicin—lung cancer	2.93e-05	0.000145	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—lung cancer	2.92e-05	0.000145	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—lung cancer	2.92e-05	0.000145	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—lung cancer	2.92e-05	0.000144	CcSEcCtD
Rasagiline—MAOB—Metabolism—STK11—lung cancer	2.89e-05	0.000215	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB3—lung cancer	2.84e-05	0.000211	CbGpPWpGaD
Rasagiline—Dizziness—Methotrexate—lung cancer	2.82e-05	0.00014	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—COL4A3BP—lung cancer	2.78e-05	0.000207	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AZIN2—lung cancer	2.78e-05	0.000207	CbGpPWpGaD
Rasagiline—Hypersensitivity—Doxorubicin—lung cancer	2.72e-05	0.000135	CcSEcCtD
Rasagiline—Vomiting—Methotrexate—lung cancer	2.71e-05	0.000134	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—JUN—lung cancer	2.7e-05	0.000201	CbGpPWpGaD
Rasagiline—Rash—Methotrexate—lung cancer	2.69e-05	0.000133	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—lung cancer	2.69e-05	0.000133	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTP1—lung cancer	2.68e-05	0.000199	CbGpPWpGaD
Rasagiline—Headache—Methotrexate—lung cancer	2.67e-05	0.000132	CcSEcCtD
Rasagiline—Asthenia—Doxorubicin—lung cancer	2.65e-05	0.000131	CcSEcCtD
Rasagiline—BCL2—Immune System—FGFR1—lung cancer	2.65e-05	0.000197	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1A—lung cancer	2.62e-05	0.000195	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BCL2L1—lung cancer	2.62e-05	0.000195	CbGpPWpGaD
Rasagiline—Pruritus—Doxorubicin—lung cancer	2.61e-05	0.000129	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PTEN—lung cancer	2.61e-05	0.000194	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CAT—lung cancer	2.61e-05	0.000194	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	2.59e-05	0.000193	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ABCB1—lung cancer	2.53e-05	0.000189	CbGpPWpGaD
Rasagiline—Nausea—Methotrexate—lung cancer	2.53e-05	0.000125	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—lung cancer	2.53e-05	0.000125	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	2.51e-05	0.000187	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TYMS—lung cancer	2.49e-05	0.000185	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EP300—lung cancer	2.49e-05	0.000185	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTM1—lung cancer	2.46e-05	0.000183	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—lung cancer	2.44e-05	0.000121	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—SRC—lung cancer	2.42e-05	0.00018	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ATP5H—lung cancer	2.36e-05	0.000176	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—POMC—lung cancer	2.35e-05	0.000175	CbGpPWpGaD
Rasagiline—Vomiting—Doxorubicin—lung cancer	2.35e-05	0.000116	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP1A1—lung cancer	2.33e-05	0.000174	CbGpPWpGaD
Rasagiline—Rash—Doxorubicin—lung cancer	2.33e-05	0.000115	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NRAS—lung cancer	2.33e-05	0.000173	CbGpPWpGaD
Rasagiline—Dermatitis—Doxorubicin—lung cancer	2.33e-05	0.000115	CcSEcCtD
Rasagiline—MAOB—Metabolism—ERCC2—lung cancer	2.31e-05	0.000172	CbGpPWpGaD
Rasagiline—Headache—Doxorubicin—lung cancer	2.31e-05	0.000115	CcSEcCtD
Rasagiline—BCL2—Immune System—KIT—lung cancer	2.3e-05	0.000171	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGF—lung cancer	2.27e-05	0.000169	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAPK3—lung cancer	2.23e-05	0.000166	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—lung cancer	2.19e-05	0.000109	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	2.17e-05	0.000161	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CASP8—lung cancer	2.14e-05	0.000159	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6R—lung cancer	2.13e-05	0.000159	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CREBBP—lung cancer	2.13e-05	0.000158	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—lung cancer	2.12e-05	0.000158	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—lung cancer	2.11e-05	0.000157	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PLBD1—lung cancer	2.1e-05	0.000157	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	2.07e-05	0.000154	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAP2K1—lung cancer	2.03e-05	0.000151	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CD—lung cancer	2.02e-05	0.00015	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—lung cancer	2e-05	0.000149	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—APOA1—lung cancer	2e-05	0.000149	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSD17B10—lung cancer	1.92e-05	0.000143	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—lung cancer	1.84e-05	0.000137	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—lung cancer	1.83e-05	0.000136	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MDM2—lung cancer	1.81e-05	0.000134	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAF1—lung cancer	1.8e-05	0.000134	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CKB—lung cancer	1.79e-05	0.000133	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—lung cancer	1.78e-05	0.000133	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MTOR—lung cancer	1.76e-05	0.000131	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—lung cancer	1.76e-05	0.000131	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD4—lung cancer	1.76e-05	0.000131	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—POMC—lung cancer	1.74e-05	0.000129	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—lung cancer	1.7e-05	0.000127	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CREBBP—lung cancer	1.69e-05	0.000126	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM2—lung cancer	1.68e-05	0.000125	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CNDP2—lung cancer	1.68e-05	0.000125	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTMR3—lung cancer	1.64e-05	0.000122	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—lung cancer	1.63e-05	0.000121	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—lung cancer	1.62e-05	0.00012	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—lung cancer	1.61e-05	0.000119	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PGAM1—lung cancer	1.59e-05	0.000119	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALB—lung cancer	1.59e-05	0.000118	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JUN—lung cancer	1.57e-05	0.000117	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—lung cancer	1.52e-05	0.000113	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2A7—lung cancer	1.52e-05	0.000113	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—lung cancer	1.52e-05	0.000113	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—lung cancer	1.5e-05	0.000112	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SDC4—lung cancer	1.49e-05	0.000111	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EP300—lung cancer	1.45e-05	0.000108	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—lung cancer	1.41e-05	0.000105	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—lung cancer	1.4e-05	0.000104	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—lung cancer	1.39e-05	0.000103	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—lung cancer	1.36e-05	0.000101	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—lung cancer	1.36e-05	0.000101	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RRM1—lung cancer	1.36e-05	0.000101	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA3—lung cancer	1.36e-05	0.000101	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK3—lung cancer	1.3e-05	9.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—B4GALT5—lung cancer	1.27e-05	9.48e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA4—lung cancer	1.24e-05	9.23e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—lung cancer	1.24e-05	9.19e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	1.21e-05	9.02e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—lung cancer	1.21e-05	9e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA2—lung cancer	1.21e-05	8.99e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—lung cancer	1.17e-05	8.68e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA1—lung cancer	1.17e-05	8.67e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—EP300—lung cancer	1.15e-05	8.58e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCC3—lung cancer	1.15e-05	8.58e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKR1C1—lung cancer	1.12e-05	8.31e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UGT1A1—lung cancer	1.08e-05	8.06e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—lung cancer	1.07e-05	7.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GNG11—lung cancer	1.05e-05	7.78e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.04e-05	7.74e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDOA—lung cancer	9.95e-06	7.4e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—lung cancer	9.92e-06	7.38e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA3—lung cancer	9.66e-06	7.19e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—lung cancer	9.5e-06	7.06e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	9.49e-06	7.06e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ADCY1—lung cancer	9.4e-06	6.99e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCG2—lung cancer	9.4e-06	6.99e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPGDS—lung cancer	9.22e-06	6.86e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO2—lung cancer	9.22e-06	6.86e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPP2R1B—lung cancer	9.16e-06	6.81e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	9.04e-06	6.72e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—lung cancer	8.94e-06	6.65e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GCLC—lung cancer	8.84e-06	6.57e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2A6—lung cancer	8.84e-06	6.57e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	8.8e-06	6.55e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—lung cancer	8.76e-06	6.52e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—lung cancer	8.53e-06	6.35e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO1—lung cancer	8.38e-06	6.23e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	8.35e-06	6.21e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	8.24e-06	6.13e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2E1—lung cancer	7.51e-06	5.59e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NQO1—lung cancer	7.43e-06	5.53e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	7.28e-06	5.41e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	7.21e-06	5.36e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—lung cancer	6.97e-06	5.19e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—STK11—lung cancer	6.7e-06	4.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	6.29e-06	4.68e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—lung cancer	6.2e-06	4.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CAT—lung cancer	6.03e-06	4.49e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	6e-06	4.46e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCB1—lung cancer	5.87e-06	4.36e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMS—lung cancer	5.76e-06	4.29e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM1—lung cancer	5.69e-06	4.24e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1A1—lung cancer	5.4e-06	4.02e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ERCC2—lung cancer	5.35e-06	3.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—APOA1—lung cancer	4.63e-06	3.45e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.44e-06	3.3e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—lung cancer	4.23e-06	3.15e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—POMC—lung cancer	4.03e-06	2.99e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CREBBP—lung cancer	3.92e-06	2.92e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—lung cancer	3.72e-06	2.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALB—lung cancer	3.67e-06	2.73e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—lung cancer	3.24e-06	2.41e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—lung cancer	3.21e-06	2.39e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—lung cancer	2.8e-06	2.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EP300—lung cancer	2.67e-06	1.99e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—lung cancer	1.98e-06	1.47e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—lung cancer	1.61e-06	1.2e-05	CbGpPWpGaD
